Stroke is one of the leading causes of mortality and long-term disability worldwide. Nearly one in four patients with a history of stroke will experience a recurrent event in the future. To mitigate this risk, clinical guidelines generally recommend that specialists prescribe antiplatelet or anticoagulant therapy, alongside lifestyle modifications.
The use of blood thinners (anticoagulants) helps prevent thrombotic events and reduces the probability of recurrent, often severe strokes. These medications play an especially critical role in managing atrial fibrillation and other high-risk cardioembolic complications. According to existing studies, anticoagulant therapy can reduce the risk of stroke by approximately 64%.
Although these drugs demonstrate high clinical efficacy and significantly lower the probability of recurrent stroke, their use is accompanied by an increased risk of bleeding. Specifically, one of the most severe and life-threatening complications of anticoagulant therapy is hemorrhage within the brain or its surrounding spaces, known as hemorrhagic stroke.
Consequently, modern strategies for secondary stroke prevention face a complex clinical dilemma: achieving effective suppression of thrombus formation without provoking life-threatening hemorrhagic complications.
Eliminating this clinical imbalance is precisely the goal of Asundexian, a novel oral anticoagulant whose efficacy and safety profile were evaluated within the framework of the international, Phase III OCEANIC-STROKE trial. The study results were published in the authoritative scientific journal The New England Journal of Medicine and were hailed by specialists as a major advancement in the field of secondary stroke prevention.
Asundexian is an orally administered, selective anticoagulant (a class of medications that targetedly inhibit blood clotting factors) that primarily targets coagulation Factor XIa (FXIa). This factor plays a crucial role in the process of pathological thrombosis, yet participates relatively minimally in the mechanisms of physiological hemostasis. Accordingly, inhibition of FXIa is considered a promising therapeutic approach that provides prevention of pathological clot formation against the backdrop of a lower risk of bleeding complications.
“Asundexian selectively inhibits Factor XIa (FXIa), targeting a component of the coagulation cascade that is increasingly recognized as more important for pathological thrombosis than for physiological hemostasis. This contrasts with available anticoagulants, including Factor Xa inhibitors, which disrupt core processes essential for both clot formation and hemostasis. Factor XI occupies a unique position in the intrinsic coagulation pathway, primarily acting as an amplifier of thrombin generation. During vascular injury, intense exposure to tissue factor activates the extrinsic pathway, generating a robust thrombin response sufficient for hemostasis with only limited participation of FXI. In contrast, during intrinsic pathological processes—such as when a cholesterol plaque ruptures within a vessel—the body cannot instantaneously activate its powerful, protective clotting mechanisms. At this point, Factor XIa (FXIa) steps in, functioning as an ‘amplifier’: it facilitates the gradual growth and stabilization of the thrombus, which can ultimately lead to complete vessel occlusion and the development of a stroke,” stated trial co-principal investigator Dr. Ashkan Shoamanesh, a senior scientist at the Population Health Research Institute (PHRI) and Doctor of Medicine.
More than 12,300 patients from 37 countries worldwide participated in the OCEANIC-STROKE trial. The average age of the participants was 68 years, with approximately one-quarter being over the age of 75. Women accounted for 33% of the enrolled patients. Approximately 95% of the participants had recently experienced a non-cardioembolic ischemic stroke—meaning a stroke not caused by cardiac pathology—while the remainder had experienced a high-risk transient ischemic attack (TIA).
Within the trial, patients were randomly assigned to two groups: the first group was prescribed 50 milligrams (mg) of Asundexian in combination with standard antiplatelet therapy, while the second group received a placebo alongside standard therapy.
The obtained results demonstrated that the use of Asundexian was associated with a 26% reduction in the risk of recurrent ischemic stroke. Furthermore, a 31% decrease in the incidence of fatal or disabling strokes was recorded. It is particularly noteworthy that this clinical benefit was achieved without any increase in the risk of intracranial hemorrhage or other severe hemorrhagic complications.
Scientists anticipate that Asundexian will bring clinical benefits to patients with non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA) who remain at an elevated risk of recurrence despite standard antiplatelet therapy. This drug will not replace the control of baseline risk factors, statin therapy, blood pressure management, smoking cessation, and adequate antiplatelet treatment; however, it may become an additional effective tool for selected high-risk patients.
For approximately half a century, aspirin monotherapy served as the foundational treatment for secondary stroke prevention. Against this backdrop, Asundexian is regarded as one of the first major advancements in the secondary prevention of the majority of ischemic strokes, beyond short courses of dual antiplatelet therapy.
Despite these encouraging results, Asundexian is currently still considered an investigational drug and is not officially approved for clinical use. Specialists emphasize that additional studies, long-term follow-up, and real-world clinical practice data analysis are essential to fully evaluate the drug’s efficacy and safety profile across diverse populations.
Nevertheless, if ongoing and future trials confirm the current findings, Asundexian could bring about a significant breakthrough in stroke management and become one of the most important innovations in medicine and neurology in recent decades.
Source: medicalnewstoday.com
